Fibroblast activation protein-targeted radioligand therapy has generated enormous excitement, but early clinical agents have underdelivered, leaving chemical innovation as the field’s most lasting legacy, according to Thomas Hope, MD, of the University of California San Francisco (UCSF). Hope delivered that assessment October 18 at the European Association of Nuclear Medicine annual meeting.
Diagnostic Promise Versus Therapeutic Shortfalls
FAP serves as a highly effective diagnostic imaging tool because it is overexpressed on cancer-associated fibroblasts across virtually all tumor types. FAP-based PET radiotracers feature clean biodistribution with no salivary gland, liver, or splenic uptake, prompting Hope to describe the target as potentially having pan-tumor appeal comparable to pembrolizumab in radioligand therapy.
Despite that diagnostic success, early therapeutic agents show tumor uptake in only the single digits or low teens and fail to sustain durable binding. Results from the phase I LUMIERE trial evaluating the peptidomimetic compound lutetium-177 FAP-2286 to improve tumor residence time have proven discouraging. Hope noted that the majority of patients experience disease progression right after their first dose because insufficient radiation reaches the tumor.
Physical Separation and Radionuclide Physics
Tumor cells and FAP-positive fibroblasts are physically separated by an average gap of roughly 250 micrometers, a distance that limits treatment efficacy based on radionuclide selection. Yttrium-90 emits high-energy electrons capable of delivering an estimated 60% to 70% of its dose across that span, whereas lutetium-177 reaches only 10% to 15%. Alpha emitters fall even shorter, treating only the cancer-associated fibroblasts, which remain highly radiation-resistant.
Next-Generation Engineering and Research Spillovers
Investigators are exploring next-generation strategies to boost uptake and retention, including dimers, tetramers, albumin binders for extended intravascular half-life, and covalent warheads for permanent tumor binding. At UCSF, researchers developed a fibroblast restricted interactive protein construct designed for local activation by FAP within the tumor microenvironment, which has shown promise in animal models.
The primary value of investments in FAP research may ultimately lie in chemical innovations that spill over to other, more densely overexpressed targets such as CA9, GPC3, and ACP3. Hope concluded that the broader field will benefit significantly from the chemistry lessons learned during FAP agent development.
Frequently Asked Questions
Why do alpha emitters fail to treat FAP-positive tumors effectively?
Alpha emitters cannot cross the 250-micrometer physical gap separating tumor cells from FAP-positive fibroblasts. Consequently, they only irradiate the cancer-associated fibroblasts, which are naturally radiation-resistant.
What specific trial results have disappointed researchers?
Phase I results from the LUMIERE trial evaluating lutetium-177 FAP-2286 showed that the majority of patients experience disease progression immediately following their first dose due to low tumor residence time and inadequate radiation delivery.
Which alternative targets are expected to benefit from FAP research?
Researchers expect the chemical innovations developed for FAP agents to transfer to other highly overexpressed targets, specifically CA9, GPC3, and ACP3.
Related reading